Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.
about
Minireview: Challenges and opportunities in development of PPAR agonistsA newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.Successful drug development despite adverse preclinical findings part 2: examples.PPARgamma and MEK Interactions in CancerThe role of the toxicologic pathologist in the biopharmaceutical industry.Examining the safety of PPAR agonists - current trends and future prospects.Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies.CKD-501, a novel selective PPARγ agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks.Discontinued drugs in 2006: renal, endocrine and metabolic drugs.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Letter: the risk of bladder cancer in korean diabetic subjects treated with pioglitazone (diabetes metab j 2012;36:371-8).Proliferative and molecular effects of the dual PPARalpha/gamma agonist tesaglitazar in rat adipose tissues: relevance for induction of fibrosarcoma.Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells.Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist.Strain-related differences in urine composition of male rats of potential relevance to urolithiasis.Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer.Commentary on "Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two-year bioassay is no longer necessary".Trans-species comparison of PPAR and RXR expression by rat and human urothelial tissues.
P2860
Q33631921-C324B4A8-EA42-40FE-855B-E6A3A50C67D0Q34527082-727F4E98-E921-482D-93A0-8064360F39E7Q34659408-483C495C-B4DF-411B-B639-BD29A979BFA2Q35603965-96CE6B50-2ACA-4C76-95DB-8DA29AB4493FQ36737285-BF468CE0-201D-4F81-B55E-7CFB151F09ADQ37924048-0047D29C-42AC-4126-A023-B17233DFC752Q38058381-35965A03-4851-468B-9B05-92579F8C584FQ38061184-5E6BFA92-235E-492B-92C5-9042304B642FQ38446975-F3631978-492B-4631-9FAC-33B34624FB09Q38460231-3FFF987D-63C0-4955-A3DE-867F50430DE2Q38641190-05C85DEF-BFBA-42E8-A581-26E2227402FBQ41839186-408E8C28-7E3D-4F68-8ED3-004ADB8CB55FQ42754588-48B86EBB-AA22-49CA-AA72-B439796D9640Q42968936-68F28BE3-C7FE-42C1-BD0C-C8796C9C32A9Q43287595-C1458BF8-10F6-49AB-97A1-11A1426D8A5FQ46043672-E1761F2C-BF44-435B-97C0-A4D453877F46Q47782346-10BADA94-66F0-4746-BFA5-0A8329AA6CC0Q53302209-C967377D-CB58-45AF-AE3B-0B5EB1F20AF0Q53321831-4AFB5049-A3F1-44B1-96A3-6F4F9A66BE3C
P2860
Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Rodent carcinogenicity profile ...... nd gamma agonist muraglitazar.
@en
Rodent carcinogenicity profile ...... nd gamma agonist muraglitazar.
@nl
type
label
Rodent carcinogenicity profile ...... nd gamma agonist muraglitazar.
@en
Rodent carcinogenicity profile ...... nd gamma agonist muraglitazar.
@nl
prefLabel
Rodent carcinogenicity profile ...... nd gamma agonist muraglitazar.
@en
Rodent carcinogenicity profile ...... nd gamma agonist muraglitazar.
@nl
P2093
P2860
P356
P1476
Rodent carcinogenicity profile ...... nd gamma agonist muraglitazar.
@en
P2093
Beth E Schilling
Borge Ulland
C Robbie Waites
Daniel Minnema
Lora L Arnold
Mark A Dominick
Richard Voelker
Samuel M Cohen
Sarah H Tannehill-Gregg
Thomas P Sanderson
P2860
P304
P356
10.1093/TOXSCI/KFM083
P577
2007-04-10T00:00:00Z